[Cancer Cell] Researchers discovered that the commensal fungus Candida albicans synergizes with Fusobacterium nucleatum to promote colorectal cancer pathogenesis and contributes to poor patient outcomes.

[Nature Cancer] Using serial in vivo orthotopic passaging, investigators developed an immunocompetent mouse model of metastatic colorectal cancer.

[Experimental & Molecular Medicine] Cannabidiol-a nonpsychotomimetic phytocannabinoid derived from the Cannabis sativa plant-was found to dramatically improve body weight loss of mice and stimulate Lgr5⁺ intestinal stem cells proliferation upon a lethal dose of irradiation.

[Cancer Immunology Research] Scientists investigated the tumor-intrinsic factors contributing to tumor microenvironment formation and evaluated genotype-based combination strategies to enhance the efficacy of immunotherapy in colorectal cancer.

[Cell Death & Disease] Researchers used spheroid culture combined with serum deprivation to enrich and identify dormancy-like colorectal cancer cells in vitro and characterized their dormancy-like phenotype by G0/G1 phase arrest, suppressed proliferation, and radio-resistance.

[Cell Death & Disease] Investigators reported that Sel-1 Suppressor of Lin-12-Like 3 (SEL1L3) protein resided on the ER membrane can effectively prevent hydroxymethylglutaryl reductase degradation protein 1-mediated endoplasmic reticulum associated degradation process via dual mechanisms.

[British Journal of Cancer] The authors identified the mechanisms of acquired chemoresistance in colorectal cancer and developed innovative targeted therapies.

[Translational Oncology] Researchers identified a mechanistic NAT10–N4-acetylcytidine (ac⁴C)–CDK4 regulatory axis that stabilizes CDK4 mRNA, promotes G1/S transition, and drives colorectal cancer progression.

[Clinical & Translational Oncology] Scientists evaluate the prevalence and clinical relevance of HER2 status differences between primary gastric cancers and metastatic lesions.

[Alloplex Biotherapeutics, Inc.] Alloplex Biotherapeutics, Inc. announced that the US FDA has granted Fast Track Designation to SUPLEXA for the treatment of patients with colorectal cancer of the MSI-H phenotype.

[British Journal of Cancer] Whilst inhibitors of the RAF-MEK-ERK-RSK pathway have demonstrated clinical utility in other cancers this has not been realized in prostate cancer. The reasons for this include a lack of predictive biomarkers for, and the unique landscape of pathway activation.

[Cell Reports] Using single-cell RNA sequencing of transgenic adenocarcinoma of the mouse prostate mice across pathological stages, scientists found an early neuroendocrine-initiating cluster marked by elevated HOXD11, conserved in human neuroendocrine prostate cancer.